
# LETTER TO THE EDITOR

# Rhabdomyomatous Differentiation in Primary Wilms Tumor and Hepatic Metastases After Chemotherapy and All-Trans-Retinoic Acid in Combination With Interferon-α

To the Editor: A 4.5-year-old male was presented with severe abdominal distension and dyspnea. A computed tomography (CT) scan revealed a tumor approximately 20 cm in diameter arising from the left kidney, and bilateral pulmonary and hepatic metastases were also noted. A percutaneous biopsy of the renal tumor was performed and pathological examination showed a classic triphasic pattern of Wilms tumor without anaplasia.

A diagnosis of Stage IV favorable histology Wilms tumor was made, and he began preoperative chemotherapy with vincrinstine, actinomycin-D, and epirubicin. An episode of life-threatening sepsis with congestive heart failure was noted as he completed a 6-week course of chemotherapy. Additionally, the tumors became larger on the follow-up CT scan. Then he received chemotherapy consisting of cyclophosphamide, etoposide, carboplatin, as well as radiotherapy. He developed septic shock after the third course of chemotherapy, and there was no significant tumor regression. As there was little improvement in alleviating the symptoms resulting from the tumors, his parents decided on no further chemotherapy. After his condition stabilized, he began to receive all-trans-retinoic acid (ATRA) in combination with interferon- $\alpha$  (IFN- $\alpha$ ) as reported by Adamson et al. [1]. No severe adverse effects were observed, and ATRA/IFN-α therapy was continued for 10 months. He then underwent a left nephrectomy along with wedge biopsies of hepatic nodules. The renal tumor, measuring 16 cm × 16 cm × 12 cm, consisted of about 10% necrosis, 3% blastema, and stroma with rhabdomyomatous differentiation which was further confirmed by immunohistochemical staining for muscle specific desmin and actin (Fig. 1).



**Fig. 1.** The section of renal tumor reveals a mature appearance of rhabdomyomatous differentiation. Interlacing bundles of cells with eccentric eosinophilic cytoplasm and strap cells are seen (H&E stain, magnification ×400).

© 2011 Wiley-Liss, Inc. DOI 10.1002/pbc.23204 Published online in Wiley Online Library (wileyonlinelibrary.com). The hepatic specimens also showed metastatic tumor cells undergoing a maturation process of rhabdomyomatous differentiation. Follow-up imaging studies continued to demonstrate multiple pulmonary and hepatic nodules without change in size or number for 9 years since stopping therapy.

Wilms tumor arises from embryonic renal precursors. Differentiation-inducing therapy can be an alternative treatment modality with tolerable side effects, especially for critically ill patients. In a phase I trial of ATRA/IFN- $\alpha$  therapy for children with refractory cancers, a 3-year-old child with recurrent Wilms tumor had maturation of renal and pulmonary tumors after 1-month therapy [1]. While in the phase II trial, there were no complete or partial responses in 14 children with recurrent Wilms tumor [2]. A lack of radiographic response does not always represent treatment failure if tumor cells undergo differentiation rather than apoptosis [3]. Further studies are needed.

# **ACKNOWLEDGMENT**

The study was supported partially by grants from the Department of Health (North 98017) and the China Medial University Hospital (DMR-99-052).

Yu-Hua Chao, MD
Department of Pediatrics
School of Medicine
Chung Shan Medical University Hospital
Taichung, Taiwan

Han-Ping Wu, MD
Department of Pediatrics
Buddhist Tzu-Chi General Hospital
Taichung Branch, Taichung, Taiwan

I-Ping Chiang, MD
Department of Pathology
China Medical University Hospital
Taichung, Taiwan

Grant sponsor: Department of Health; Grant number: North 98017; Grant sponsor: China Medial University Hospital; Grant number: DMR-99-052.

\*Correspondence to: Kang-Hsi Wu, MD, Department of Pediatrics, Children's Hospital and School of Chinese Medicine, China Medical University and Hospitals, Taichung, Taiwan, No. 2 Yuh-Der Road, North District, Taichung 404, Taiwan.

E-mail: d5284@mail.cmuh.org.tw

Received 17 February 2011; Accepted 25 April 2011

# 2 Chao et al.


Ching-Tien Peng, PhD
Department of Pediatrics
Children's Hospital and School of Chinese Medicine
China Medical University and Hospitals
Department of Biotechnology and Bioinformatics
Asia University, Taichung, Taiwan

Yung-Li Yang, MD
Department of Laboratory Medicine
Department of Pediatrics
College of Medicine
National Taiwan University, Taipei, Taiwan

Kang-Hsi Wu, MD\*
Department of Pediatrics
Children's Hospital and School of Chinese Medicine
China Medical University and Hospitals
Taichung, Taiwan

# **REFERENCES**

- Adamson PC, Reaman G, Finklestein JZ, et al. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-α2a in pediatric patients with refractory cancer. J Clin Oncol 1997;15: 3330–3337.
- Adamson PC, Matthay KK, O'Brien M, et al. A phase 2 trial of all-trans-retinoic acid in combination with interferon-α2A in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study. Pediatr Blood Cancer 2007;49:661–665.
- Anderson J, Slater O, McHugh K, et al. Response without shrinkage in bilateral Wilms tumor: Significance of rhabdomyomatous histology. J Pediatr Hematol Oncol 2002;24:31–34.




# USING E-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION

# **Required Software**


Adobe Acrobat Professional or Acrobat Reader (version 7.0 or above) is required to e-annotate PDFs. Acrobat 8 Reader is a free download: <a href="http://www.adobe.com/products/acrobat/readstep2.html">http://www.adobe.com/products/acrobat/readstep2.html</a>. For help with system requirements, go to: <a href="http://www.adobe.com/support/">http://www.adobe.com/support/</a>.

Once you have Acrobat Reader on your PC and open the proof, you will see the Commenting Toolbar (if it does not appear automatically go to Tools>Commenting>Commenting Toolbar). If these options are not available in your Adobe Reader menus then it is possible that your Adobe version is lower than 7 or the PDF has not been prepared properly.

# PDF Annotations (Adobe Reader version 7 or 8) – Commenting Toolbars look like this:



(PC, Adobe version 8, right-click on title bar (Comment & Markup) to show additional icons)



# PDF Annotations (Adobe Reader version 9)

If you experience problems annotating files in Adobe Acrobat Reader 9 then you may need to change a preference setting in order to edit.

The default for the Commenting toolbar is set to 'off' in version 9. To change this setting select 'Edit | Preferences', then 'Documents' (at left under 'Categories'), then select the option 'Never' for 'PDF/A View Mode'. (the Commenting toolbar is the same as in version 8).



# PLEASE DO NOT ATTEMPT TO EDIT THE ARTICLE TEXT ITSELF

# TO INDICATE INSERT, REPLACE, OR REMOVE TEXT

# Insert text

Click the 'Text Edits' button on the Commenting toolbar. Click to set the cursor location in the text and simply start typing. The text will appear in a commenting box. You may also cut-and-paste text from another file into the commenting box. Close the box by clicking on 'x' in the top right-hand corner. It can be deleted by right clicking (for the PC, ctrl-click on the Mac) on it and selecting 'Delete'.

# Replace text

Click the 'Text Edits' button on the Commenting toolbar. To highlight the text to be replaced, click and drag the cursor over the text. Then simply type in the replacement text. The replacement text will appear in a commenting box. You may also cut-and-paste text from another file into this box. To replace formatted text (an equation for example) please Attach a file (see below).

#### Remove text

Click the 'Text Edits' button on the Commenting toolbar. Click and drag over the text to be deleted. Then press the delete button on your keyboard. The text to be deleted will then be struck through.

#### HIGHLIGHT TEXT/MAKE A COMMENT

Click on the 'Highlight' button on the commenting toolbar. Click and drag over the text. To make a comment, double click on the highlighted text and simply start typing.

# ATTACH A FILE

Click on the 'Attach a file' button on the commenting toolbar. Click on the figure, table or formatted text to be replaced. A window will automatically open allowing you to attach a file. To make a comment, go to 'General' and then 'Description' in the 'Properties' window. A graphic will appear indicating the insertion of a file.

#### LEAVE A NOTE/COMMENT

Click on the 'Note Tool' button on the commenting toolbar. Click to set the location of the note on the document and simply start typing. <u>Do not use this feature</u> to make text edits.

#### REVIEW

To review your changes, click on the 'Show' button on the commenting toolbar. Choose 'Show Comments List'. Navigate by clicking on a correction in the list. Alternatively, double click on any mark-up to open the commenting box.

# **UNDO/DELETE CHANGE**

To undo any changes made, use the right click button on your mouse (for PCs, Ctrl-Click for Mac). Alternatively click on the 'Edit' in the main Adobe menu and then 'Undo'. You can also delete edits using the right click (Ctrl-Click on the Mac) and selecting 'Delete'.

# SEND YOUR ANNOTATED PDF FILE BACK TO WILEY VIA <a href="mailto:pbcprod@wiley.com">pbcprod@wiley.com</a>

Save the annotations to your file and return as an e-mail. Before returning, please ensure you have answered any questions raised on the Query form that you have inserted all the corrections: later inclusion of any subsequent corrections cannot be guaranteed.

**Note:** Comprehensive instructions are provided within your PDF file: to access these instructions please click on the Comments and Markup menu in the main tool bar, or click on Help.

# **COPYRIGHT TRANSFER AGREEMENT**



Date:	Contributor name:	
Manuscript number (Edi	itorial office only):	
Re: Manuscript entitled		
		(the "Contribution")
for publication in		(the "Journal")
published by		("Wiley-Blackwell").

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable Wiley-Blackwell to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement signed and returned as directed in the Journal's instructions for authors as soon as possible. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.** 

#### A. COPYRIGHT

- 1. The Contributor assigns to Wiley-Blackwell, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to publish, republish, transmit, sell, distribute and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.
- 2. Reproduction, posting, transmission or other distribution or use of the final Contribution in whole or in part in any medium by the Contributor as permitted by this Agreement requires a citation to the Journal and an appropriate credit to Wiley-Blackwell as Publisher, and/or the Society if applicable, suitable in form and content as follows: (Title of Article, Author, Journal Title and Volume/Issue, Copyright © [year], copyright owner as specified in the Journal). Links to the final article on Wiley-Blackwell's website are encouraged where appropriate.

#### **B. RETAINED RIGHTS**

Notwithstanding the above, the Contributor or, if applicable, the Contributor's Employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution.

# C. PERMITTED USES BY CONTRIBUTOR

- **1. Submitted Version.** Wiley-Blackwell licenses back the following rights to the Contributor in the version of the Contribution as originally submitted for publication:
  - **a.** After publication of the final article, the right to self-archive on the Contributor's personal website or in the Contributor's institution's/employer's institutional repository or archive. This right extends to both intranets and the Internet. The Contributor may not update the submission version or replace it with the published Contribution. The version posted must contain a legend as follows: This is the pre-peer reviewed version of the following article: FULL CITE, which has been published in final form at [Link to final article].
  - **b.** The right to transmit, print and share copies with colleagues.
- **2. Accepted Version.** Re-use of the accepted and peer-reviewed (but not final) version of the Contribution shall be by separate agreement with Wiley-Blackwell. Wiley-Blackwell has agreements with certain funding agencies governing reuse of this version. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement. NIH grantees should check the box at the bottom of this document.

- **3. Final Published Version.** Wiley-Blackwell hereby licenses back to the Contributor the following rights with respect to the final published version of the Contribution:
  - **a.** Copies for colleagues. The personal right of the Contributor only to send or transmit individual copies of the final published version in any format to colleagues upon their specific request provided no fee is charged, and further-provided that there is no systematic distribution of the Contribution, e.g. posting on a listserve, website or automated delivery.
  - **b.** Re-use in other publications. The right to re-use the final Contribution or parts thereof for any publication authored or edited by the Contributor (excluding journal articles) where such re-used material constitutes less than half of the total material in such publication. In such case, any modifications should be accurately noted.
  - **c.** Teaching duties. The right to include the Contribution in teaching or training duties at the Contributor's institution/place of employment including in course packs, e-reserves, presentation at professional conferences, in-house training, or distance learning. The Contribution may not be used in seminars outside of normal teaching obligations (e.g. commercial seminars). Electronic posting of the final published version in connection with teaching/training at the Contributor's institution/place of employment is permitted subject to the implementation of reasonable access control mechanisms, such as user name and password. Posting the final published version on the open Internet is not permitted.
  - **d.** Oral presentations. The right to make oral presentations based on the Contribution.

# 4. Article Abstracts, Figures, Tables, Data Sets, Artwork and Selected Text (up to 250 words).

- **a.** Contributors may re-use unmodified abstracts for any non-commercial purpose. For on-line uses of the abstracts, Wiley-Blackwell encourages but does not require linking back to the final published versions.
- **b.** Contributors may re-use figures, tables, data sets, artwork, and selected text up to 250 words from their Contributions, provided the following conditions are met:
  - (i) Full and accurate credit must be given to the Contribution.
  - (ii) Modifications to the figures, tables and data must be noted. Otherwise, no changes may be made.
  - (iii) The reuse may not be made for direct commercial purposes, or for financial consideration to the Contributor.
  - (iv) Nothing herein shall permit dual publication in violation of journal ethical practices.

#### D. CONTRIBUTIONS OWNED BY EMPLOYER

- 1. If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/employer which must sign this Agreement (in addition to the Contributor's signature) in the space provided below. In such case, the company/employer hereby assigns to Wiley-Blackwell, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in paragraph A above.
- 2. In addition to the rights specified as retained in paragraph B above and the rights granted back to the Contributor pursuant to paragraph C above, Wiley-Blackwell hereby grants back, without charge, to such company/employer, its subsidiaries and divisions, the right to make copies of and distribute the final published Contribution internally in print format or electronically on the Company's internal network. Copies so used may not be resold or distributed externally. However the company/employer may include information and text from the Contribution as part of an information package included with software or other products offered for sale or license or included in patent applications. Posting of the final published Contribution by the institution on a public access website may only be done with Wiley-Blackwell's written permission, and payment of any applicable fee(s). Also, upon payment of Wiley-Blackwell's reprint fee, the institution may distribute print copies of the published Contribution externally.

#### **E. GOVERNMENT CONTRACTS**

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government under the contribution of the Contribution and may authorize others to do so, for official U.S. Government under the contribution and may authorize others to do so, for official U.S. Government contract or grant the contribution and may authorize others to do so, for official U.S. Government contract or grant the contribution and may authorize others to do so, for official U.S. Government contract or grant, the U.S. Government contract or grant the U.S. Government contract or gran

ment purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end)

#### F. COPYRIGHT NOTICE

The Contributor and the company/employer agree that any and all copies of the final published version of the Contribution or any part thereof distributed or posted by them in print or electronic format as permitted herein will include the notice of copyright as stipulated in the Journal and a full citation to the Journal as published by Wiley-Blackwell.

# G. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. If the Contribution was prepared jointly, the Contributor agrees to inform the co-Contributors of the terms of this Agreement and to obtain their signature to this Agreement or their written permission to sign on their behalf. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in Wiley-Blackwell's permissions form or in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury.

Contributor-owned work				
ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY	Contributor's signature	Date		
	Type or print name and title			
	Co-contributor's signature	<u>Date</u>		
	Type or print name and title			
Company/Institution-owned work				
(made-for-hire in the course of employment)	Company or Institution (Employer-for-Hire)	Date		
	Authorized signature of Employer	Date		
	Note to U.S. Government Employees			
U.S. Government work				
U.K. Government work (Crown Copyright)  Note to U.K. Government Employees  The rights in a Contribution prepared by an employee of a U.K. government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. U.K. government authors should submit a signed declaration form together with this Agreement. The form can be obtained via http://www.opsi.gov.uk/advice/crown-copyright/copyright-guidance/publication-of-articles-written-by-ministers-and-civil-servants.htm				
Other Government work	Note to Non-U.S., Non-U.K. Government Employees If your status as a government employee legally prevents you from signing this Agreement, please contact the editorial office.			
NIH Grantees	Note to NIH Grantees Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of Contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available.			

12 months after publication. For further information, see www.wiley.com/go/nihmandate.



# Additional reprint and journal issue purchases

Should you wish to purchase additional copies of your article, please click on the link and follow the instructions provided: https://caesar.sheridan.com/reprints/redir.php?pub=10089&acro=PBC

Corresponding authors are invited to inform their co-authors of the reprint options available.

Please note that regardless of the form in which they are acquired, reprints should not be resold, nor further disseminated in electronic form, nor deployed in part or in whole in any marketing, promotional or educational contexts without authorization from Wiley. Permissions requests should be directed to mailto: <a href="mailto:permissionsus@wiley.com">permissionsus@wiley.com</a>

For information about 'Pay-Per-View and Article Select' click on the following link: http://wileyonlinelibrary.com/ppv



# **COLOR REPRODUCTION IN YOUR ARTICLE**

Color figures were included with the final manuscript files that we received for your article. Because of the high cost of color printing, we can only print figures in color if authors cover the expense.

Please indicate if you would like your figures to be printed in color or black and white. Color images will be reproduced online in Wiley *InterScience* at no charge, whether or not you opt for color printing.

Failure to return this form will result in the publication of your figures in black and white.

JOURNAL Pediatric Blood & Cancer		VOLUME	VOLUME ISSUE		
TITLE OF MANUSCRIPT					
MS. NO	NO. OF COLOR PAGES	AUTHOR(S)			
No. Color Pages	Color Charges	No. Color Pages	Color Charges	No. Color Pages	Color Charges
1	950	5	3400	9	5850
2	1450	6	3900	10	6350
3	1950	7	4400	11	6850
4	2450	8	4900	12	7350
***Dloggo gombosh	the Production Edito	 	am)far a arrata if rra	u harra mana than 10	magas of solow***
r lease contact	the Froduction Edito	n (pocprod@wney.co	omptor a quote ir you	u nave more man 12	pages of color
☐ Please print my f	igures in black and whi	te		\$	
Please check one:	nust be paid in currency an Check enclosed harge to: Amer	d 🗌 E	<u> </u>	Credit Card MasterCard	
Credit Card No		Signature		Ex	p. Date
BILL TO: Name			Purchase Order No.		
Institution			Phone		
Address					
			Fax		
			E-mail		